nach oben

Current Treatment Options in Neurology

Erschienen in:

01.04.2019 | Headache (JR Couch, Section Editor)

Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists

verfasst von: Jill C. Rau, MD, PhD, David W. Dodick, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Migraine causes more years of life lived with disability than almost any other condition in the world and can significantly impact the lives of individuals with migraine, their families, and society. The use of medication for the prevention of migraine is an integral component to reducing disability caused by migraine. There are many different drug classes that have been investigated and shown efficacy in migraine prophylaxis. This article examines several of the classes of medications that are used for migraine preventive treatment, specifically, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, serotonin antagonists, alpha-adrenergic agonists, and N-methyl-d-aspartic acid receptor antagonists.

Recent findings

There have been randomized control trials investigating medications in these drug classes since the most recent guidelines for migraine prevention in adults were published by the American Academy of Neurology, American Headache Society, and the Canadian Headache Society. In these investigations, enalapril, candesartan, and memantine all demonstrated efficacy for migraine prevention. The evidence for these and the aforementioned drug classes are reviewed.

Summary

When oral medications are being selected for migraine prevention, comorbid and coexistent medical conditions, concomitant medications, patient preference, and pregnancy and breast-feeding plans should be considered. Within the drug classes discussed, memantine and candesartan have a moderate level of evidence for efficacy.

Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53(3):427–36. https://doi.org/10.1111/head.12074.CrossRefPubMed

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017;390(10100):1211–59. https://doi.org/10.1016/s0140-6736(17)32154-2.CrossRef

Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–8.CrossRef

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9. https://doi.org/10.1212/01.wnl.0000252808.97649.21.CrossRefPubMed

Andrasik F. What does the evidence show? Efficacy of behavioural treatments for recurrent headaches in adults. Neurol Sci. 2007;28(Suppl 2):S70–7. https://doi.org/10.1007/s10072-007-0754-8.CrossRefPubMed

Probyn K, Bowers H, Mistry D, Caldwell F, Underwood M, Patel S, et al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. BMJ Open. 2017;7(8):e016670. https://doi.org/10.1136/bmjopen-2017-016670.CrossRefPubMedPubMedCentral

• Rosenberg L, Butler N, Seng EK. Health behaviors in episodic migraine: why behavior change matters. Curr Pain Headache Rep. 2018;22(10):65. https://doi.org/10.1007/s11916-018-0721-5. These authors highlight lifestyle and behavioral changes that are beneficial for reducing migraine burden.CrossRefPubMed

Calhoun AH, Ford S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache. 2007;47(8):1178–83. https://doi.org/10.1111/j.1526-4610.2007.00780.x.CrossRefPubMed

Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Lasting improvement of medication-overuse headache after brief intervention - a long-term follow-up in primary care. Eur J Neurol. 2017;24(7):883–91. https://doi.org/10.1111/ene.13318.CrossRefPubMed

10.

• Buse DC, Andrasik F. Behavioral medicine for migraine. Neurol Clin. 2009;27(2):445–65. https://doi.org/10.1016/j.ncl.2009.01.003. This paper reviews the evidence for behavioral therapies for migraine prevention.CrossRefPubMed

11.

• Grimsrud KW, Halker Singh RB. Emerging treatments in episodic migraine. Curr Pain Headache Rep. 2018;22(9):61. https://doi.org/10.1007/s11916-018-0716-2 This paper describes available and upcoming neuromodulatory treatments for migraine.CrossRefPubMed

12.

•• Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–45. https://doi.org/10.1212/WNL.0b013e3182535d20. These are the most up-to-date guidelines in the United States for the prevention of episodic migraine in adults.CrossRefPubMedPubMedCentral

13.

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of neurology. Neurology. 2016;86(19):1818–26. https://doi.org/10.1212/WNL.0000000000002560.CrossRefPubMedPubMedCentral

14.

•• Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59. These are the most up-to-date guidelines in Canada for the prevention of episodic migraine in adults.PubMed

15.

• Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–32. https://doi.org/10.1177/0333102413515348. This study reports efficacy of the ARB, candesartan, for migraine prophylaxis. It was published after both of the recent North American guidelines for migraine prevention in adults and lend additional evidence for the safety, tolerability and efficacy of candesartan for migraine prevention.CrossRefPubMed

16.

• Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. Int J Prev Med. 2013;4(1):72–7. This study reports efficacy of the NMDAR-antagonist, memantine, for migraine prophylaxis. It was published after both of the recent North American guidelines for migraine prevention in adults. It introduces good evidence for the use of a different class of medication for migraine prevention.PubMedPubMedCentral

17.

• Noruzzadeh R, Modabbernia A, Aghamollaii V, Ghaffarpour M, Harirchian MH, Salahi S, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache. 2016;56(1):95–103. https://doi.org/10.1111/head.12732. This study reports efficacy of the NMDAR-antagonist, memantine, for migraine prophylaxis. It was published after both of the recent North American guidelines for migraine prevention in adults. It introduces good evidence for the use of a different class of medication for migraine prevention.CrossRefPubMed

18.

Paterna S, di Pasquale P, Martino S, Arrostuto A, Ingurgio NC, Parrinello G, et al. Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study. Clin Ter. 1992;141(12):475–81.PubMed

19.

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ (Clin Res). 2001;322(7277):19–22.CrossRef

20.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–9.CrossRef

21.

Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009;29(9):921–7. https://doi.org/10.1111/j.1468-2982.2008.01825.x.CrossRefPubMed

22.

Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. J R Coll Gen Pract. 1978;28(195):587–90.PubMedPubMedCentral

23.

Anthony M, Lance JW, Somerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust. 1972;1(26):1343–6.PubMed

24.

Boisen E, Deth S, Hubbe P, Jansen J, Klee A, Leunbach G. Clonidine in the prophylaxis of migraine. Acta Neurol Scand. 1978;58(5):288–95.CrossRef

25.

Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. J Fam Pract. 1989;29(2):153–6. discussion 7-8.PubMed

26.

Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. Acta Neurol Scand. 1979;60(4):214–7.CrossRef

27.

Kallanranta T, Hakkarainen H, Hokkanen E, Tuovinen T. Clonidine in migraine prophylaxis. Headache. 1977;17(4):169–72.CrossRef

28.

Kass B, Nestvold K. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial. Acta Neurol Scand. 1980;61(6):351–6.CrossRef

29.

Louis P, Schoenen J, Hedman C. Metoprolol v. clonidine in the prophylactic treatment of migraine. Cephalalgia. 1985;5(3):159–65. https://doi.org/10.1046/j.1468-2982.1985.0503159.x.CrossRefPubMed

30.

Lynggaard F, Ostergaard F. [Clonidine in prevention of migraine. Report of a double-blind study of 38 patients referred for neurological assessment]. Ugeskr Laeger. 1975;137(3):149–51.PubMed

31.

Mondrup K, Moller CE. Prophylactic treatment of migraine with clonidine. A controlled clinical trial. Acta Neurol Scand. 1977;56(5):405–12.CrossRef

32.

Ryan RE Sr, Diamond S, Ryan RE Jr. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. Headache. 1975;15(3):202–10.CrossRef

33.

Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and follow-up. Lancet (London, England). 1972;1(7747):403–7.CrossRef

34.

Sillanpaa M. Clonidine prophylaxis of childhood migraine and other vascular headache. A double blind study of 57 children. Headache. 1977;17(1):28–31.CrossRef

35.

Sills M, Congdon P, Forsythe I. Clonidine and childhood migraine: a pilot and double-blind study. Dev Med Child Neurol. 1982;24(6):837–41.PubMed

36.

Sjaastad O, Stensrud P. 2-(2.6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155 or Catapresan) as a prophylactic remedy against migraine. Acta Neurol Scand. 1971;47(1):120–2.CrossRef

37.

Stensrud P, Sjaastad O. Clonidine (Catapresan)-double-blind study after long-term treatment with the drug in migraine. Acta Neurol Scand. 1976;53(3):233–6.CrossRef

38.

Wilkinson M. Preliminary report on the use of clonidine (Boehringer Ingelheim) in the treatment of migraine. Res Clin Stud Headache. 1970;3:315–20.PubMed

39.

Elkind AH, Webster C, Herbertson RK. Efficacy of guanfacine in a double blind parallel study for migraine prophylaxis. Cephalalgia. 1989;9(Suppl. 10).CrossRef

40.

Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470–82.CrossRef

41.

Leandri M, Rigardo S, Schizzi R, Parodi CI. Migraine treatment with nicardipine. Cephalalgia. 1990;10(3):111–6. https://doi.org/10.1046/j.1468-2982.1990.1003111.x.CrossRefPubMed

42.

Shukla R, Garg RK, Nag D, Ahuja RC. Nifedipine in migraine and tension headache: a randomised double blind crossover study. J Assoc Physicians India. 1995;43(11):770–2.PubMed

43.

McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology. 1989;39(2 Pt 1):284–6.CrossRef

44.

Gerber WD, Diener HC, Scholz E, Niederberger U. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia. 1991;11(1):37–45. https://doi.org/10.1046/j.1468-2982.1991.1101037.x.CrossRefPubMed

45.

Lamsudin R, Sadjimin T. Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. Headache. 1993;33(6):335–8.CrossRef

46.

Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache. 1989;29(4):215–8.CrossRef

47.

European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Migraine-Nimodipine European Study Group (MINES). Headache. 1989;29(10):639–42.

48.

European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Migraine-Nimodipine European Study Group (MINES). Headache. 1989;29(10):633–8.

49.

Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia. 1985;5(1):39–43. https://doi.org/10.1046/j.1468-2982.1985.0501039.x.CrossRefPubMed

50.

Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavapalan M, Wilkinson M, et al. Nimodipine in migraine prophylaxis. Cephalalgia. 1988;8(4):269–72. https://doi.org/10.1046/j.1468-2982.1988.0804269.x.CrossRefPubMed

51.

Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache. 1983;23(3):106–9.CrossRef

52.

Bussone G, Baldini S, D'Andrea G, Cananzi A, Frediani F, Caresia L, et al. Nimodipine versus flunarizine in common migraine: a controlled pilot trial. Headache. 1987;27(2):76–9.CrossRef

53.

Formisano R, Falaschi P, Cerbo R, Proietti A, Catarci T, D'Urso R, et al. Nimodipine in migraine: clinical efficacy and endocrinological effects. Eur J Clin Pharmacol. 1991;41(1):69–71. https://doi.org/10.1007/bf00280110.CrossRefPubMed

54.

Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. Cephalalgia. 1987;7(1):7–13. https://doi.org/10.1046/j.1468-2982.1987.0701007.x.CrossRefPubMed

55.

Micieli G, Tucco M, Agostinis C, Mancuso A, Papalia F, Sinforiani E. Nimodipine vs. pizotifen in common migraine: results of a double-clind cross-over trial. Cephalalgia. 1985;5(Suppl 3):532–3.CrossRef

56.

Gawel MJ. A double-blind, cross over study of nimopidipine versus pizotyline in a common and classical migraine. Cephalalgia. 1987;7(Suppl 6):453–4.CrossRef

57.

Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology. 1984;34(7):973–6.CrossRef

58.

Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA. 1983;250(18):2500–2.CrossRef

59.

Solomon GD. Verapamil and propranolol in migraine prophylaxis: a double blind crossover study. Headache. 1986;26.

60.

Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache. 1981;21(6):235–9.CrossRef

61.

Frenken CW, Nuijten ST. Flunarizine, a new preventive approach to migraine. A double-blind comparison with placebo. Clin Neurol Neurosurg. 1984;86(1):17–20.CrossRef

62.

Mentenopoulos G, Manafi T, Logothetis J, Bostantzopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia. 1985;5(Suppl 2):135–40. https://doi.org/10.1177/03331024850050s225.CrossRefPubMed

63.

Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6(1):7–14. https://doi.org/10.1046/j.1468-2982.1986.0601007.x.CrossRefPubMed

64.

Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache. 1991;31(9):613–5.CrossRef

65.

al Deeb SM, Biary N, Bahou Y, al Jaberi M, Khoja W. Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population). Headache. 1992;32(9):461–2.CrossRef

66.

Cerbo R, Casacchia M, Formisano R, Feliciani M, Cusimano G, Buzzi MG, et al. Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis. Cephalalgia. 1986;6(1):15–8. https://doi.org/10.1046/j.1468-2982.1986.0601015.x.CrossRefPubMed

67.

Louis P, Spierings EL. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia. 1982;2(4):197–203. https://doi.org/10.1046/j.1468-2982.1982.0204197.x.CrossRefPubMed

68.

Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache. 1986;26(2):83–5.CrossRef

69.

Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48(3):223–6.PubMed

70.

Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache. 1990;30(11):710–5.CrossRef

71.

Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache. 1977;17(3):109–12.CrossRef

72.

Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand. 1977;56(1):17–28.CrossRef

73.

Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Opin. 1975;3(2):68–71. https://doi.org/10.1185/03007997509113649.CrossRefPubMed

74.

Sjaastad O, Stensrud P. Appraisal of BC-105 in migraine prophylaxis. Acta Neurol Scand. 1969;45(5):594–600.CrossRef

75.

• Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–82. https://doi.org/10.1016/S1474-4422(17)30435-0. This is an exceptional and recent review of the current understanding of migraine pathophysiology.CrossRefPubMed

76.•

Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019:333102418821662. https://doi.org/10.1177/0333102418821662. This paper reviews the newest class of migraine preventive medications which were designed specifically for migraine, are targeted against CGRP receptors or ligand and were released in the past year.CrossRef

77.

Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, et al. Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase activating peptide. J Pharmacol Exp Ther. 2019. https://doi.org/10.1124/jpet.118.253443.CrossRef

78.

Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–61. https://doi.org/10.1002/ana.20778.CrossRefPubMed

79.

Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283(2):R287–95. https://doi.org/10.1152/ajpregu.00123.2002.CrossRefPubMed

80.

Ginsburg J, O'Reilly B, Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. Br J Obstet Gynaecol. 1985;92(11):1169–75.CrossRef

81.

Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL. Alpha(2C)-adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002;300(1):282–90.CrossRef

82.

Lavand'homme PM, Ma W, De Kock M, Eisenach JC. Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002;97(4):972–80.CrossRef

83.

Ripa P, Ornello R, Pistoia F, Carolei A, Sacco S. The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev Neurother. 2014;14(9):1043–55. https://doi.org/10.1586/14737175.2014.946408.CrossRefPubMed

84.

Pietrobon D. Calcium channels and migraine. Biochim Biophys Acta. 2013;1828(7):1655–65. https://doi.org/10.1016/j.bbamem.2012.11.012.CrossRefPubMed

85.

Monzani D, Genovese E, Pini LA, Di Berardino F, Alicandri Ciufelli M, Galeazzi GM, et al. Nimodipine in otolaryngology: from past evidence to clinical perspectives. Acta Otorhinolaryngol Ital. 2015;35(3):135–45.PubMedPubMedCentral

86.

Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543–52.CrossRef

87.

Pelzer N, Stam AH, Haan J, Ferrari MD, Terwindt GM. Familial and sporadic hemiplegic migraine: diagnosis and treatment. Curr Treat Options Neurol. 2013;15(1):13–27. https://doi.org/10.1007/s11940-012-0208-3.CrossRefPubMed

88.

Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol. 1991;197(2–3):221–3.CrossRef

89.

Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14(1):27–35. https://doi.org/10.1007/s11940-011-0150-9.CrossRefPubMed

90.

DaSilva AF, Nascimento TD, Jassar H, Heffernan J, Toback RL, Lucas S, et al. Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. Neurology. 2017;88(17):1634–41. https://doi.org/10.1212/wnl.0000000000003861.CrossRefPubMedPubMedCentral

91.

Wober C, Brucke T, Wober-Bingol C, Asenbaum S, Wessely P, Podreka I. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia. 1994;14(3):235–40. https://doi.org/10.1046/j.1468-2982.1994.014003235.x.CrossRefPubMed

92.

Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC. Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia. 1995;15(6):489–93. https://doi.org/10.1046/j.1468-2982.1995.1506489.x.CrossRefPubMed

93.

Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13(2):89–93. https://doi.org/10.1046/j.1468-2982.1993.1302089.x.CrossRefPubMed

94.

Charles A, Brennan K. Cortical spreading depression-new insights and persistent questions. Cephalalgia. 2009;29(10):1115–24. https://doi.org/10.1111/j.1468-2982.2009.01983.x.CrossRefPubMedPubMedCentral

95.

Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006;46(Suppl 1):S39–44.CrossRef

96.

Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15(2):361–70. https://doi.org/10.1007/s13311-018-0616-5.CrossRefPubMedPubMedCentral

97.

Ramadan NM. Glutamate and migraine: from Ikeda to the 21st century. Cephalalgia. 2014;34(2):86–9. https://doi.org/10.1177/0333102413499646.CrossRefPubMed

98.

Kilinc E, Guerrero-Toro C, Zakharov A, Vitale C, Gubert-Olive M, Koroleva K, et al. Serotonergic mechanisms of trigeminal meningeal nociception: implications for migraine pain. Neuropharmacology. 2017;116:160–73. https://doi.org/10.1016/j.neuropharm.2016.12.024.CrossRefPubMed

99.

Yuan H, Silberstein SD. Histamine and migraine. Headache. 2018;58(1):184–93. https://doi.org/10.1111/head.13164.CrossRefPubMed

100.

Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. AHRQ Technical Reviews. Drug treatments for the prevention of migraine headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999.

101.

Neurology AAo. Clinical Practice Guideline Process Manual. St. Paul: The American Academy of Neurology; 2011.

102.

•• Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PloS One. 2015;10(7):e0130733. https://doi.org/10.1371/journal.pone.0130733. This is a comprehensive systematic review of oral medications used for migraine propylaxis.CrossRefPubMedPubMedCentral

103.

Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache. 1988;28(4):260–2.CrossRef

104.

Diamond S, Freitag FG. A double-blind trial of flunarizine in migraine prophylaxis. Headac Q. 1992;4:169–72.

105.

Pini LA, Ferrari A, Guidetti G, Galetti G, Barbieri L, Sternieri E. Effectiveness of flunarizine in altering electronystagmographic patterns in migraine patients: a preliminary report. Int J Clin Pharmacol Res. 1986;6(1):27–32.PubMed

106.

Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P. [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol. 2003;36(10):907–12.PubMed

107.

Pini LA, Ferrari A, Guidetti G, Galetti G, Sternieri E. Influence of flunarizine on the altered electronystagmographic (ENG) recordings in migraine. Cephalalgia. 1985;5(Suppl 2):173–5. https://doi.org/10.1177/03331024850050s233.CrossRefPubMed

108.

Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. N Z Med J. 1971;73(464):5–9.PubMed

109.

Cleland PG, Barnes D, Elrington GM, Loizou LA, Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol. 1997;38(1):31–8. https://doi.org/10.1159/000112899.CrossRefPubMed

110.

Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res Clin Exp. 1971;13(1):63–8.PubMed

111.

Kangasniemi P. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. Headache. 1979;19(4):219–22.CrossRef

112.

Ryan RE. Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache. Headache. 1968;8(3):118–26.CrossRef

113.

Krakowski AJ, Engisch R. A new agent for chemotherapy of migraine headaches: a controlled study. Psychosomatics. 1973;14(5):302–8. https://doi.org/10.1016/S0033-3182(73)71324-4.CrossRefPubMed

114.

Kahan A, Weber S, Amor B, Guerin F, Degeorges M. Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon. N Engl J Med. 1983;308(18):1102–3.PubMed

115.

Paterna S, Martino SG, Campisi D, Cascio Ingurgio N, Marsala BA. [Evaluation of the effects of verapamil, flunarizine, diltiazem, nimodipine and placebo in the prevention of hemicrania. A double-blind randomized cross-over study]. Clin Ter. 1990;134(2):119–25.PubMed

116.

Yuan Q, Liu DL, Yu LS, Zhang QF. [Flunarizine in the prophylaxis of vestibular migraine:a randomized controlled trial]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;30(10):805–10. https://doi.org/10.13201/j.issn.1001-1781.2016.10.012.CrossRefPubMed

117.

Liu F, Ma T, Che X, Wang Q, Yu S. The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol. 2017;8:524. https://doi.org/10.3389/fneur.2017.00524.CrossRefPubMedPubMedCentral

118.

Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorhinolaryngol. 2014;271(11):2931–6. https://doi.org/10.1007/s00405-013-2786-4.CrossRefPubMed

119.

Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust. 1968;1(2):54–5.PubMed

120.

Ryan RE. BC-105 a new preparation for the interval treatment of migraine--a double blind evaluation compared with a placebo. Headache. 1971;11(1):6–18.CrossRef

121.

Rizzoli P, Loder EW. Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache. 2011;51(8):1323–35. https://doi.org/10.1111/j.1526-4610.2011.01985.x.CrossRefPubMed

122.

Loder EW, Rizzoli P. Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache. 2011;51(8):1336–45. https://doi.org/10.1111/j.1526-4610.2011.01986.x.CrossRefPubMed

Titel: Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists
verfasst von: Jill C. Rau, MD, PhD
David W. Dodick, MD
Publikationsdatum: 01.04.2019
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 4/2019
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-019-0559-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Beta-Blockers for Migraine Prevention: a Review Article

OnabotulinumtoxinA in Migraine and Other Headaches: Review and Update

Antidepressants for Preventive Treatment of Migraine

Editor’s Note: a Brief History of Preventative Antimigraine Therapy (PAMT)

When to Consider Prophylactic Antimigraine Therapy in Children with Migraine

Invited Commentary on Preventive Anti-Migraine Therapy (PAMT)

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie